Identification of broad, potent antibodies to functionally constrained regions of SARS-CoV-2 spike following a breakthrough infection
Why the study?
The global emergence of new SARS-CoV-2 variants of concern has compromised the efficacy of vaccines and therapeutic antibodies, requiring discovery of broad and potent antibodies.
Population
Neutralizing monoclonal antibodies isolated from an individual with a Delta VOC breakthrough infection
Comparison
Isolated monoclonal antibodies vs approved therapeutic mAbs across SARS-CoV-2 variants
Design
In vitro neutralization and epitope-mapping study
Authors
Discussion
Loading...
Member takes
Implication
May advance durable SARS-CoV-2 therapies; leaves open clinical translation pending validation.
Structured PICO
P
Population
Monoclonal antibodies isolated from an individual who experienced a breakthrough infection with the SARS-CoV-2 Delta variant of concern
I
Intervention
Four broad and potent neutralizing monoclonal antibodies (mAbs)
C
Comparator
Previously approved therapeutic mAbs
O
Outcome
Neutralization potency against SARS-CoV-2 variants (Wuhan-Hu-1, Delta, Omicron BA.4/BA.5, XBB.1.5, BQ.1.1) and SARS-CoV-1 in pseudovirus-based and authentic virus assayssurrogate
The discovery of highly potent mAbs targeting conserved regions of the SARS-CoV-2 spike protein provides potential new therapeutic options resilient to viral escape.
Cite This Study
Guenthoer et al. (2023) studied this question.